The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Sildenafil for Treatment of Erectile Dysfunction in Men With Diabetes: A Randomized Controlled Trial
Abstract
CONTEXT: Erectile dysfunction is common in men with diabetes. OBJECTIVE: To assess the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with diabetes. DESIGN: A multicenter, randomized, double-blind, placebo-controlled, flexible dose-escalation study conducted May through November 1996. SETTING: Patients' homes and 19 clinical practice centers in the United States. PATIENTS: A total of 268 men (mean age, 57 years) with erectile dysfunction (mean duration, 5.6 years) and diabetes (mean duration, 12 years). INTERVENTIONS: Patients were randomized to receive sildenafil (n = 136) or placebo (n = 132) as needed, but not more than once daily, for 12 weeks. Patients took the study drug or placebo 1 hour before anticipated sexual activity. The starting dose of sildenafil citrate was 50 mg, with the option to adjust the dose to 100 mg or 25 mg based on efficacy and tolerability, to be taken as needed. MAIN OUTCOME MEASURES: Self-reported ability to achieve and maintain an erection for sexual intercourse according to the International Index of Erectile Function and adverse events. RESULTS: Two hundred fifty-two patients (94%) completed the study (131/136 in the sildenafil group, 121/132 in the placebo group). By intention-to-treat analysis, at 12 weeks, 74 (56%) of 131 patients in the sildenafil group reported improved erections compared with 13 (10%) of 127 patients in the placebo group (P<.001). The proportion of men with at least 1 successful attempt at sexual intercourse was 61 % (71/ 117) for the sildenafil group vs 22% (25/114) for the placebo group (P<.001). Adverse events related to treatment were reported for 22 (16%) of 136 patients taking sildenafil and 1 (1%) of 132 patients receiving placebo. The most common adverse events were headache (11% sildenafil, 2% placebo), dyspepsia (9% sildenafil, 0% placebo), and respiratory tract disorder (6% sildenafil, 2% placebo), predominantly sinus congestion or drainage. The incidence of cardiovascular adverse events was comparable for both groups (3% sildenafil, 5% placebo). CONCLUSION: Oral sildenafil is an effective and well-tolerated treatment for erectile dysfunction in men with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinlay, J. B. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)34871-1 · Cited by 5,074
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
The Design and Analysis of Clinical Experiments
Fleiss, J. L. (1999) · Wiley eBooks · doi:10.1002/9781118032923 · Cited by 4,819
The Design and Analysis of Clinical Experiments.
Hills, M., & Fleiss, J. L. (1987) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2982050 · Cited by 3,261
Andersson, K. E., & Wagner, G. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.1.191 · Cited by 1,119
Boolell, M., Mj, A., Sa, B., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Ih, O., & Gingell, C. (1996) · PubMed · Cited by 1,067
Oral Sildenafil in the Treatment of Erectile Dysfunction
(1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390121 · Cited by 622
The prevalence of diabetic impotence
McCulloch, D. K., Campbell, I. W., Wu, F. C., Prescott, R. J., & Clarke, B. F. (1980) · Diabetologia · doi:10.1007/bf00251005 · Cited by 429
Nitric Oxide in the Penis: Physiology and Pathology
Burnett, A. L. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65369-2 · Cited by 350
Role of Nitric Oxide in the Physiology of Erection1
Burnett, A. L. (1995) · Biology of Reproduction · doi:10.1095/biolreprod52.3.485 · Cited by 252
Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men
Price, D. E., Gingell, J. C., Gepi-Attee, S., Wareham, K., Yates, P., & Boolell, M. (1998) · Diabetic Medicine · Cited by 119
Kaiser, F. E., & Korenman, S. G. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90408-1 · Cited by 82
Sexual dysfunction in the diabetic patient with hypertension
Zemel, P. C. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)91102-2 · Cited by 62
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., et al. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)62474-1 · Cited by 61
Diabetes-Related Impotence in the Elderly
Whitehead, E. D., & Klyde, B. J. (1990) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30580-9 · Cited by 46
Impotence in diabetes mellitus
Close, C. F., & Ryder, R. E. J. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110307 · Cited by 38
Cited by
Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1553 · Cited by 2,044
The International Index of Erectile Function (IIEF): a state-of-the-science review
Rosen, R. C., Cappelleri, J. C., & Gendrano, N. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900857 · Cited by 1,044
(2005) · doi:10.1016/j.ucl.2005.08.007 · Cited by 759
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2030 · Cited by 629
Erectile Dysfunction in Diabetes Mellitus
Malavige, L. S., & Levy, J. C. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01168.x · Cited by 444
Metadata
- Authors
- Rendell, M. S., Rajfer, J., Wicker, P. A., Smith, M. D., & for the Sildenafil Diabetes Study Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1999-02-03
- Volume
- 281
- Issue
- 5
- Pages
- 421
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2062907730
- Cited by
- 610
- References
- 16
- FWCI
- 29.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.